drugset / Trial / NCT04219865

Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection

NCT04219865

Phase 1 Completed 40 enrolled Nanjing Yoko Biomedical Co., Ltd.
RandomizedFactorialTriple-blindBasic science

Summary

Study on the Safety, Tolerance and Pharmacokinetics of Single-dose, Increasing and Loading Dose and Maintenance Dose Sequential Intravenous Infusion of Compound Edaravone Injection in Chinese Healthy Volunteers

Timeline

Start
2019-06-05
Primary completion
2019-08-16
Completion
2019-08-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator 2-Aminoethanesulfonic Acid Unknown 600 mg Intravenous
Comparator 2-Aminoethanesulfonic Acid Unknown 1200 mg Intravenous
Comparator 2-Aminoethanesulfonic Acid Unknown 1800 mg Intravenous
Comparator 2-Aminoethanesulfonic Acid Unknown 2400 mg Intravenous
Comparator Edaravone Unknown 30 mg Intravenous
Comparator Edaravone Unknown 60 mg Intravenous
Comparator Edaravone Unknown 90 mg Intravenous
Comparator Edaravone Unknown 120 mg Intravenous

Indications

No indication recorded.